Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Iprivask Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering
The Iprivask market has seen significant growth, driven by a variety of factors. Historically, this growth has been fueled by the high incidence of thromboembolic disorders, the widespread adoption of low molecular weight heparin (LMWH) in hospitals, and its proven safety over unfractionated heparin. The increasing number of surgical procedures and an aging population also contribute to this trend.
Looking forward, the market is expected to continue expanding due to the rising prevalence of cardiovascular diseases, the growth in orthopedic and surgical care, and the persistent demand for reliable and predictable anticoagulation therapies. The preference for LMWH, continued focus on thrombosis prevention, and the expansion of surgical prophylaxis uses are key trends shaping the future of the market. A notable driver of market growth is the increasing number of hip replacement surgeries, spurred by aging populations, rising obesity rates, and advancements in surgical techniques. These surgeries often require anticoagulants like Iprivask (desirudin) to prevent deep vein thrombosis (DVT).
Additionally, the rising incidence of venous thromboembolism (VTE) is expected to drive market growth. Factors contributing to the increase in VTE cases include aging populations, obesity, immobility, and heightened cancer rates. Improved detection methods have also led to more cases being diagnosed. Iprivask plays a crucial role in preventing and treating VTE by inhibiting blood clot formation, thus supporting its market expansion.
Healthcare expenditure is another critical factor supporting Iprivask market growth. Rising healthcare spending driven by advancements in medical technology and an increasing demand for quality healthcare services enhances access to medications like Iprivask. Moreover, Iprivask is marketed primarily towards surgical patients, high-risk groups, and the elderly, all benefiting from its anticoagulant properties.
Geographically, North America held the largest share of the Iprivask market in 2025, but Asia-Pacific is projected to experience the fastest growth rate. Important markets include countries like the USA, Canada, Australia, China, and several European nations. Tariffs have impacted the market by increasing costs, thus encouraging regional production and supporting long-term supply reliability.
The Iprivask market consists of sales of desirudin for injection, with values reflecting 'factory gate' pricing. This includes all revenues generated from sales of goods and services within specified geographic markets. The Iprivask market research report provides comprehensive statistics, market trends, and detailed industry insights necessary for stakeholders to thrive in this dynamic sector.
Major Trends
- Continued Use of Anticoagulant Therapies
- Preference for Low Molecular Weight Heparins
- Growth in Thrombosis Prevention Protocols
- Expansion of Surgical Prophylaxis Use
- Focus on Safer Anticoagulation Management
For more information about this report visit https://www.researchandmarkets.com/r/n33bce
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
